Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Bob Holland, Dan Quayle

Premium

Oxford Gene Technology has named Bob Holland as its new chief medical officer.

Holland previously was VP and head of AstraZeneca's Personalized Healthcare and Biomarkers division, which he helped create.

In his new role, Holland will lead clinical affairs across OGT's business areas, including working with R&D and commercial teams to develop clinical development programs to expand the company's next-generation sequencing and microarray cancer profiling solutions, and its biomarker programs for prostate and colorectal cancers.


Former US Vice President Dan Quayle has been elected to the TGen Foundation's board of directors.

The foundation is the fundraising branch of the Translational Genomics Research Institute.

Quayle is chairman of the private equity firm Cerberus Global Investments. He is a resident of Paradise Valley, Ariz., and he grew up in Phoenix.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.